Immunogenicity and Safety of Verorab™ in Indian Population
Rabies
About this trial
This is an interventional treatment trial for Rabies focused on measuring rabies;, rabies post-exposure;, category III
Eligibility Criteria
Inclusion Criteria: Subject with WHO category III rabies exposure Subject aged at least 2 years old (day of second birthday) Exclusion Criteria: Subject unable to comply with the follow-up schedule of the protocol Delayed post-exposure treatment (>72 hours between incident and treatment Subject bitten by an observable animal at the inclusion visit Subject with immune-compromised or underlying diseases which may lead to inferior immune response Subject with known pregnancy at the time of inclusion Subject enrolled or scheduled to be enrolled in another clinical study. Subject with acute febrile illness/ axillary temperature > 37.5 degree celsius Subject in whom blood sampling will be difficult. Subject receiving chloroquine or other anti-malarial treatment Subject receiving immunosuppressive therapy, other immune-modifying drug or cytotoxic drugs Subject with known chronic illnesses (ie. heart, lung, kidney, liver) including immunosuppressive diseases (cancer, HIV, etc.) Previous rabies immunization Subject having received any vaccine within the previous 30 days, except tetanus toxoid and tetanus immunoglobulin Subject with clinical signs of rabies Subject with known allergy to vaccine components (e.g. neomycin) Subject who received blood and/or plasma transfusion within the past 3 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group 1
Group 2
Group 3
Participants on Thai Red Cross, TRC-ID regimen
Participants on Zagreb-IM regimen
Participants on Essen-IM regimen.